US Bancorp DE Has $379.39 Million Stake in Abbott Laboratories $ABT

US Bancorp DE cut its stake in Abbott Laboratories (NYSE:ABT) by 1.3% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 2,832,552 shares of the healthcare product maker’s stock after selling 37,572 shares during the period. US Bancorp DE’s holdings in Abbott Laboratories were worth $379,393,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Cloud Capital Management LLC bought a new position in shares of Abbott Laboratories during the third quarter worth about $29,000. Guerra Advisors Inc acquired a new position in Abbott Laboratories during the 3rd quarter worth approximately $31,000. Anfield Capital Management LLC grew its stake in shares of Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock worth $32,000 after acquiring an additional 104 shares in the last quarter. Delos Wealth Advisors LLC acquired a new stake in shares of Abbott Laboratories in the second quarter valued at approximately $32,000. Finally, Bridge Generations Wealth Management LLC bought a new stake in shares of Abbott Laboratories in the third quarter worth $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on ABT. Royal Bank Of Canada lowered their price target on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Argus dropped their target price on Abbott Laboratories from $150.00 to $140.00 in a report on Tuesday, January 27th. The Goldman Sachs Group reduced their price target on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating for the company in a research report on Friday, January 23rd. Oppenheimer lowered their price target on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Finally, William Blair raised Abbott Laboratories to a “strong-buy” rating in a report on Thursday, November 20th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, Abbott Laboratories has an average rating of “Moderate Buy” and an average price target of $137.05.

Insider Activity at Abbott Laboratories

In other news, Director Daniel J. Starks bought 10,000 shares of the stock in a transaction dated Wednesday, February 4th. The shares were bought at an average price of $108.73 per share, for a total transaction of $1,087,300.00. Following the completion of the purchase, the director owned 6,738,817 shares in the company, valued at approximately $732,711,572.41. This trade represents a 0.15% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 0.46% of the company’s stock.

Abbott Laboratories Trading Up 0.2%

Shares of Abbott Laboratories stock opened at $114.76 on Thursday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.58 and a quick ratio of 1.24. The business has a fifty day simple moving average of $117.70 and a two-hundred day simple moving average of $125.47. Abbott Laboratories has a 1 year low of $105.27 and a 1 year high of $141.23. The company has a market capitalization of $199.42 billion, a price-to-earnings ratio of 30.85, a P/E/G ratio of 1.82 and a beta of 0.75.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, meeting the consensus estimate of $1.50. The company had revenue of $11.46 billion for the quarter, compared to analyst estimates of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The company’s revenue was up 4.4% on a year-over-year basis. During the same period in the prior year, the firm earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, May 15th. Stockholders of record on Wednesday, April 15th will be issued a dividend of $0.63 per share. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.2%. The ex-dividend date is Wednesday, April 15th. Abbott Laboratories’s payout ratio is currently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.